Effects of dexamethasone on intracochlear inflammation and residual hearing after cochleostomy: A comparison of administration routes

Ah-Ra Lyu 1,2*, Dong Hyun Kim 1*, Seung Hun Lee 1, Dong-Sik Shin 3, Sun-Ae Shin 1,2, Yong-Ho Park 1,4*

1 Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Chungnam National University, Daejeon, Republic of Korea, 2 Department of Medical Science, College of Medicine, Chungnam National University, Daejeon, Republic of Korea, 3 Biomedical Convergence Research Center, Chungnam National University Hospital, Daejeon, Republic of Korea, 4 Brain Research Institute, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

These authors contributed equally to this work.

abstract

Preservation of residual hearing after cochlear implant is an important issue with regards to hearing performance. Various methods of steroid administration have been widely used in clinical practice to reduce inflammation and preserve residual hearing. Here we compare the effect of different routes of dexamethasone administration on intracochlear inflammation and residual hearing in guinea pig ears. Dexamethasone was delivered into the guinea pigs either through intracochlear, intratympanic or systemic route. The intracochlear concentration of dexamethasone, residual hearing, inflammatory cytokines and histopathologic changes were evaluated over time. A higher intracochlear dexamethasone concentration was observed after intracochlear administration than through the other routes. Residual hearing was better preserved with local dexamethasone administration as was supported by the reduced inflammatory cytokines, more hair cell survival and less severe intracochlear fibrosis and ossification concurrently seen in the local delivery group than in the systemic group. The results demonstrate that local dexamethasone delivery can reduce intracochlear inflammation and preserve residual hearing better than in systemically administered dexamethasone.

Introduction

Dexamethasone is a widely used steroid that has potent anti-inflammatory effect. Steroid is the treatment of choice for idiopathic sudden sensorineural hearing loss [1–3] and has been regarded as having a role in the preservation of residual hearing in cochlear implant surgery [4–6]. The expression of glucocorticoid receptor in the cochlea has become a convincing reason for steroid application in this area [7, 8]. Dexamethasone can be administered systemically...
Several reports have shown that dexamethasone, whether applied locally\cite{9–13} or systemically\cite{5, 14, 15}, was able to significantly reduce hearing loss. It is still questionable whether systemic or intratympanic injected steroid can penetrate the cochlea effectively. From a more simplistic point of view of directly delivering a drug into the cochlea, an intracochlear injection seems to be the most straightforward. However, assessing drug level inside the cochlea requires a cochleostomy or puncture of the round window membrane, both surgical approaches would be, by themselves, traumatic to the cochlea. An atraumatic and effective method of steroid delivery into the cochlea are the main goals and it is still unknown which route of delivery would be most appropriate in achieving these. In this study, we aimed to compare the effects of dexamethasone administered via different routes on intracochlear inflammation and residual hearing after cochleostomy.

**Materials and methods**

1. **Animals**

All animal experiments were approved by the Chungnam National University, Committee of the Animal Experiment (CNU00499). Ninety male albino guinea pigs, weighing 250-300g each, with normal hearing prior to surgery were enrolled in this study. Eighty-four animals were used for the experimental group with bilateral cochleostomy and this experimental group was divided into cochleostomy only group (CS), intracochlear dexamethasone group (IC), intratympanic dexamethasone group (IT) and intraperitoneal dexamethasone group (IP) (see below). Time point studies were performed (9 animals for 10, 30, and 90 minutes, 21 animals for 1 day, 12 animals for 3 days, 1 and 2 months). Thirty-six animals were used for perilymph sampling at each time point (10, 30, 90 minutes, and 1 day). Another 24 animals were used for real-time polymerase chain reactions at each time point (1 and 3 days) and 24 animals were used for immunohistochemistry (30 days, n = 12) and sectional study (60 days, n = 12). The remaining 6 animals were used as normal controls for real-time polymerase chain reactions (N = 3) and perilymph sampling (N = 3).

2. **Surgical procedure for cochleostomy and dexamethasone application**

The animals were anesthetized with intramuscular injection of combination of tiletamine HCl and zolazepam HCl 40 mg/kg (Zoletil, Virbac Animal Health, Carros, France) and xylazine 10 mg/kg (Rompun, Bayer Animal Health, Monheim, Germany). In addition, 0.5 ml of 1% lidocaine HCl was injected subcutaneously in the postauricular area for local anesthesia. The anesthetized animals were placed in a prone position on a thermoregulated heated pad. A retroauricular incision was made and blood was taken from an exposed neighboring blood vessel using an insulin syringe. The temporal bone was exposed and opened to visualize the round window membrane. A small cochleostomy was made in the bone near the round window with a sharp pick. The cochleostomy was made bilaterally. Using a micro cannula connected to the tip of a 30 gauge needle and Hamilton syringe (Hamilton Company, Reno, NV), 5 μl of dexamethasone (5mg/ml, Huons, Korea) was injected into the scala tympani through the left cochleostomy site using an infusion pump for 2 minutes. The cochleostomy site and bulla were then sealed with tissue adhesive (Durelon, 3M ESPE, Germany) and carboxylate cement (Durelon, 3M ESPE, Germany) in IC group. Similar injection method described above was also employed in the IT group except for the tip of the cannula was instead directed into the tympanum to create a tympanic bulla filled with dexamethasone. Dexamethasone (10mg/kg) was injected intraperitoneally for 3 days in the IP group. The skin incision was closed in two layers. Afterwards, the animals were allowed to recover from anesthesia, and their pain was controlled with carprofen (Rimadyl, 4mg/kg, subcutaneously, Pfizer, NY, USA). No
animal died in this set of experiments. Morbidity was limited to signs that are typical after cochleostomy, including unsteadiness and occasional head tilt. These resolved within a few days and did not worsen.

3. Auditory brainstem response

The hearing threshold shifts after surgery were evaluated in each group via auditory brainstem response (ABR) threshold at 4, 8, 16, 23 kHz, and click sound. The ABRs were recorded prior to surgery, just after surgery, at 7 days, 1 and 2 months after surgery. TDT System-3 (Tucker Davies Technologies, Gainesville, FL, USA) hardware and software were used to obtain the ABRs. The stimuli were computer generated tone pips. Subcutaneous needle electrodes were placed around the skull vertex and both infra-auricular areas. Tone bursts with duration of 4 ms and a rise-fall time of 1 ms at frequencies of 4, 8, 16, 32 kHz, and clicks were used. The sound intensity was varied by 10-dB intervals for the tone-burst sounds and by 5 dB intervals for the click sounds near the threshold. The waveforms were analyzed using a custom program (BioSig RP, ver. 4.4.1) with the researcher blinded to the treatment group. Threshold was defined as the lowest stimulus intensity to evoke a wave III response greater than 0.2 mV.

Further ABR threshold measurements were done at 7 days, 1 and 2 months after the operation. The differences in ABR thresholds were averaged across the frequency range for each cochlea to yield their individual mean rise in ABR threshold. Threshold shift was defined as the difference between preoperative and one of the postoperative values. A positive threshold shift indicated an elevation of the auditory threshold.

4. Cochlear fluid sampling and analysis

The change of dexamethasone concentration over time in the cochlea in each group was determined by measuring the amount of drug in the perilymph fluid collected from the cochlear apex done at 10, 30, 90 minutes and 1 day after surgery, as detailed previously[16]. In brief, the tympanic bulla was washed several times with lactated Ringer’s solution and suctioned out. After removal of cochlear apex mucosa, small apical cochleostomy was done with a sharp pick and about 3~4 μl perilymph was collected in hand-held graduated glass capillary tubes (IntraMARK micropipettes, BRAUBAND, Wertheim, Germany) marked at every 0.5 μl volume. Each cochlear fluid sample was analyzed using mass system (QTRAP 4000, Applied Biosystems, Carlsbad, CA) interfaced with high-performance liquid chromatography (LC-MS/MS, Agilent 1260, Agilent Technologies, Santa Clara, CA) to measure the dexamethasone concentration in the perilymph. Samples were injected into a C18 column (XBD C18, 50 mm × 2.1 mm; Agilent Technologies, Santa Clara, CA) with a mobile phase of acetonitrile:water (50:50, v/v) ran at a flow rate of 0.4 ml/min.

5. Quantitative real time polymerase chain reaction

Comparison of the early inflammatory responses between groups was done by sacrificing the animals at either 1 day or 3 days after surgery and quantitative real time polymerase chain reactions (qRT-PCR) for IL-1β, IL-6, TNF-α, and NOS2 were conducted. Interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and nitric oxide synthase 2 (NOS 2) were measured and used as indicators of inflammatory response. Dissected cochleae were ground in 1 ml of TRIZOL reagent (Invitrogen, Carlsbad, CA, USA), 200 μl of chloroform was added, mixed gently and then centrifuged at 13,000 rpm for 15 minutes. About 450 μl of supernatant was transferred to a fresh tube and the same amount of isopropanol was added, shaken for 5 minutes, and centrifuged at 13,000 rpm for 15 minutes. The resulting pellet was suspended in 1 ml of 80% ethanol (in DEPC-treated water) and centrifuged at 13,000 rpm for 15
minutes. The same procedure was performed one more time and the pellet was then washed with 100% ethanol repeatedly. RNA was dissolved in 20 μl of RNase-free water. The purified RNA was quantified using Nano drop (NanoDrop Technologies Inc., Wilmington, DE, USA) by measuring UV absorbance of 260 nm. A total of 13 μl of RNA (2 μg each) with oligo-dT primer and DEPC-treated water was pre-denatured for 10 minutes at 65˚C followed by addition of 4 μl of 5x reaction buffer, 2 μl of dNTP, 0.5 μl of RNase inhibitor, and 0.5 μl of RTase. The mixture was reverse transcribed for 1 hour at 50˚C and 5 minutes at 85˚C with the cDNA Synthesis Kit (Roche, IN, USA). The real-time reverse transcription process was performed according to the manufacturer’s procedure with SYBRgreen (Invitrogen, Grand Island, NY, USA). Comparative quantification of IL-1β, IL-6, TNF-α, and NOS2 mRNA was obtained by comparative cycle of the threshold method. The quantitative RT-PCR was performed 3 times for each sample. The details of primers used in the polymerase chain reaction to detect IL-1β, IL-6, TNF-α, and NOS2 are presented in Table 1.

6. Tissue preparation and immunohistochemistry

Selected animals were sacrificed at 1 month after surgery and cochlear tissues were obtained to assess survival of hair cells and nerve fibers. Tissues were fixed in 4% paraformaldehyde in PBS for 1 hour at room temperature. The cochlear bony walls and lateral wall tissues were first removed and the remaining cochlear tissues were prepared for immunostaining. Tissues were permeated with 0.3% Triton X-100 (Sigma–Aldrich Co., St. Louis, MO) for 10 minutes, blocked in 5% normal goat serum (Vector Laboratories, Inc., Burlingame, CA) for 30 minutes and then incubated with rabbit anti-myosin VIIa primary antibody (Proteus BioSciences, Inc., Ramona, CA) and mouse anti-NF200 primary antibody (Novus Biologicals, Littleton, CO) at a concentration of 1:200 in blocking solution overnight at 4˚C. After rinsing in PBS for 10 minutes, the tissues were incubated with the corresponding AlexaFluor 594 goat anti-rabbit secondary antibody (Molecular Probes, Eugene, OR) or AlexaFluor 488 goat anti-mouse secondary antibody (Molecular Probes, Eugene, OR) at a concentration of 1:200 in PBS for 30 minutes. After rinsing in PBS for 10 minutes, specimens were further dissected to separate individual cochlear turns and mounted on glass slides using CrystalMount (Biomeda, Foster City, CA). The specimens were observed using an epifluorescence microscope (Zeiss Axio Scope A1; Zeiss, Germany) with digital camera and the surviving hair cells were counted in each 100 μm of tissue.

Both cochleae were harvested from the animals 2 months after the operation for sectional study to assess intracochlear fibrosis and ossification. The harvested samples were placed in 4% paraformaldehyde in PBS for 2 hours, decalcified in EDTA (ethylene diamine tetra-acetic
acid, 5% nitric acid) for 3 weeks, embedded in paraffin, sectioned in the mid-modiolar plane at a thickness of 5 μm and stained with hematoxylin and eosin. The stained tissue sections were examined and representative fields photographed using a light microscope (Olympus BX51; Olympus, Tokyo, Japan). All histologic sections were examined for evidence of intracochlear fibrosis and new bone formation. The timeline for all experiments are shown in Fig 1.

7. Image processing and statistical analysis

Adjustment of image contrast, superimposition of images, and colorization of monochrome fluorescence images were performed using Adobe Photoshop (version 7.0). Statistical analysis was performed with Graphpad Prism (version 3.02, San Diego, CA, USA) and SPSS (version 16.0, SPSS Inc., Chicago, IL). ABR threshold shift and the levels of inflammatory cytokine data taken before and after the surgery in each group were compared using One-way repeated measure ANOVA and the differences between groups at each time point were compared using one-way ANOVA. The hair cell survival between groups were compared using Kruskall-Wallis test. *p values of < 0.05 were considered significant.

Results

1. ABR threshold shifts

ABR threshold shifts were increased in the CS group with the passage of time and these threshold shifts were greater in the IC and IT groups at just after surgery in all measured frequencies compared to the CS and IP groups at just after surgery. In the IC group, the differences were significant with 4, 16, 32 kHz and click at 1 month after surgery and all measured frequencies at 2 months after surgery compared to CS group (*p < 0.05). In the IT group, the differences were significant with 4 kHz at 1 month after surgery and 4, 8 kHz and click at 2 months after surgery compared to CS group (*p < 0.05). The threshold shifts in the IP group showed similar pattern with no significant differences compared to the CS group. These suggested that residual hearing was better preserved in the IC and IT groups compared to the CS and IP groups (Fig 2).
2. Changes of intracochlear dexamethasone concentration

The concentration of dexamethasone in the cochlea was highest at 10 minutes in the IC group and at 30 minutes in the IT group. It showed a declining pattern over time. Dexamethasone was not detectable in the cochlea in the IP group at any measured time points. The concentration of dexamethasone was significantly higher in the IC group at 10 and 30 minutes compared to the IT group (p < 0.05). This suggested that the IC route was a more effective method for dexamethasone delivery into the cochlea than via the IT and IP routes (Fig 3).

3. Changes of inflammatory cytokine

IL-1β, IL-6, TNF-α and NOS2 were significantly increased in the CS group compared to the normal ear at 1 day and the increase of IL-1β, IL-6, TNF-α were sustained until 3 days after surgery. IL-1β, IL-6 and NOS2 were significantly decreased in the IC, IT and IP groups compared to the CS group, while TNF-α was decreased in the IC and IP groups compared to the CS group at 1 day after surgery (p < 0.05). At 3 days after surgery, IL-1β, IL-6 and NOS2 were significantly decreased in the IC, IT and IP groups compared to the CS group, while TNF-α was decreased in the IC and IT groups compared to the CS and IP groups (p < 0.05). These suggested that the inflammatory responses in the cochlea were decreased, albeit with different patterns during the early stage, in the dexamethasone treated groups compared to the CS group (Fig 4).

4. Survival of hair cells

At 1 month after surgery, almost all the outer hair cells (OHC) were destroyed in the basal turn of the cochlea in all groups but more inner hair cells (IHC) survived in the basal turn in the IC and IT groups compared to the CS and IP groups (Fig 5A4, 5B4, 5C4 and 5D4). Hair
cell counts also showed more surviving IHCs in the 2nd turn of the cochlea in the IC, IT and IP groups and in the basal turn in the IC and IT groups. This was significantly higher in the IC group compared to the other groups (Fig 6A). OHC were better preserved in the 2nd turn of the cochlea in the IC group compared to the other groups (Fig 6B). These suggested that the auditory HCs were better preserved in the IC and IT groups compared to the CS and IP groups. It appears that dexamethasone delivered via the IC route was superior over the other methods of delivery with regards to HC survival.

5. Intracochlear histopathologic changes

Extensive ossification and fibrosis were observed in the basal turn of the cochlea in the CS (Fig 7A1 and 7A2) and IP groups (Fig 7D1 and 7D2) at 2 months after surgery. In contrast, only some fibrosis in the scala tympani without extensive ossification in the cochlea was observed in the IC (Fig 7B1 and 7B2) and IT groups (Fig 7C1 and 7C2). This suggested that inflammatory tissue response in the cochlea was less severe in the IC and IT groups compared to the CS and IP groups.

Discussion

Although cochlear implant (CI) can restore hearing even in deaf patients, preservation of residual hearing in CI is still a quite important issue. There were several reports that the
delayed reduction of CI benefits with the passage of time[17, 18], due to direct injury to the cochlea during surgery or delayed intracochlear fibrosis and ossification, may lead to residual hearing loss[19]. Furthermore, when there is a need for electro-acoustic stimulation, a method using acoustic stimulation of naive hearing with hearing aid in low frequency and electric stimulation in high frequency, the preservation of residual hearing is mandatory. An atraumatic surgery aimed at residual hearing preservation would be a very important issue for CI. With the purpose of minimizing trauma to the cochlea in mind, surgeries have changed from the traditional cochleostomy to the less traumatic round window approach[20–23] and softer atraumatic electrodes have been developed[24, 25]. Furthermore, perioperative use of steroid has gained interest. Trials to deliver the steroid with dexamethasone eluting electrode have been considered[26–30] and other potentially more effective drug delivery methods into the cochlea, such as gel and nanoparticles, are being developed [31–34]. There have been several reports about hearing preservation with steroid treatment in animal studies. Although the administration methods and dosage of dexamethasone were somewhat different, many of them showed hearing preservation and reduced adverse tissue responses such as fibrosis and ossification with dexamethasone use[10–12, 27, 31, 32, 35–38]. The same outcome was also observed in our experiment. Hearing preservation was observed in all measured frequencies.

Fig 4. Quantitative real time polymerase chain reactions at 1 and 3 days after surgery. IL-1β, IL-6, and NOS2 were significantly increased in CS group compared to the other groups at 1 day after surgery and the increased IL-1β and IL-6 were sustained until 3 days after surgery. TNF-α was significantly decreased in the IC group at 1 day and in the IC and IT groups after surgery compared to other group. The increased TNF-α was sustained until 3 days after surgery in the IP group. Asterisk indicates p<0.05.

https://doi.org/10.1371/journal.pone.0195230.g004
2 months after the surgery especially in the IC group compared to the CS, IT and IP groups. The immediate hearing losses observe were thought to be due to the loss of inner ear homeostasis such as inner ear hydrops in the IC group or the bullous space occupied by the

![Image](https://doi.org/10.1371/journal.pone.0195230.g005)

**Fig 5.** Whole-mounts of the auditory epithelium in CS (A1, A2, A3 and A4), IC (B1, B2, B3 and B4), IT (C1, C2, C3 and C4) and IP (D1, D2, D3 and D4) group at 1 month after surgery. Tissues were stained for myosin VIIa (red) to highlight the hair cells and NF-200 (green) for nerve fibers and then photographed with epifluorescence. Hair cell loss was more severe in the basal turn of the CS (A4) and IP groups (D4) compared to the IC (B4) and IT groups (C4). A1, B1, C1 and D1: Apical turn, A2, B2, C2 and D2: 3rd turn, A3, B3, C3 and D3: 2nd turn, A4, B4, C4 and D4: basal turn, OHC: outer hair cell, IHC: inner hair cell, Scale bar = 30 μm.

![Image](https://doi.org/10.1371/journal.pone.0195230.g006)

**Fig 6.** Survived hair cell counts after surgery. IHC were better preserved in the 2nd turn of the IC, IT and IP groups compared to the CS group and in the basal turn of the IC and IT groups compared to the CS and IP groups. IHC survival was significantly higher in the 2nd and basal turn of the IC group compared to other groups (A) and OHCs were better preserved in the 2nd turn of the IC group compared to other groups (B). Asterisk indicates p<0.05.

![Image](https://doi.org/10.1371/journal.pone.0195230.g006)
dexamethasone in the IT group. Histopathology showed that more hair cells survived in the ear of the IC, IT and IP groups compared to the CS group. A recent human study by Cho HS et al demonstrated that the use of preoperative systemic and intraoperative topical steroid can offer better hearing preservation compared to not using steroid and that the use of perioperative steroid can help minimize inner ear damage after CI[5]. Rajan GP et al also showed that preoperative intratympanic methyl prednisone (glucocorticoid) can improve and stabilize hearing preserved after CI[4]. It seems that the use of steroid in CI surgery is being widely considered.

Steroid can be administered either systemically or locally. Local routes of steroid administration targeting the cochlea can be done via intratympanic or intracochlear methods. Theoretically, a direct intracochlear steroid delivery would result in the highest concentration of the medicine in the inner ear than the other routes. A local route also significantly minimizes the possibility of systemic side effects that often occur in systemically administrated drugs. Unfortunately, this direct intracochlear delivery is currently possible only through a cochleostomy or by puncturing the round window membrane during CI surgery; both surgical approaches are traumatic to the cochlea which by themselves may cause residual hearing loss. According to Bird PA et al, administration of dexamethasone via the intratympanic route resulted in a much higher perilymph drug concentration and much lower plasma concentrations compared with systemic administration in their human study[14]. It is still doubtful whether steroid can effectively cross the round window membrane or oval window in the intratympanic route or the blood labyrinth barrier in the systemic route to reach the cochlea and achieve therapeutic levels [39, 40]. In this study, we compared the intracochlear dexamethasone concentration in

---

Fig 7. Histopathology of the cochlea in the CS (A1 and A2), IC (B1 and B2), IT (C1 and C2) and IP groups (D1 and D2) at 2 months after surgery. More extensive ossification (arrow head) and fibrosis (asterisk) were observed in the basal turn of the CS (A1 and A2) and IP groups (D1 and D2) than the IC (B1 and B2) and IT (C1 and C2) groups. Scale bar = 1 mm in A1, and 100 μm in A2, B2, C2 and D2.

https://doi.org/10.1371/journal.pone.0195230.g007
relation to the different administration routes against the passage of time. The highest concentration was observed in the IC group compared to the IT and IP groups, and it was not even detectable in the IP group until 1 day after surgery. This means that from the point of view of steroid concentration in the inner ear, the IC route appears to be more effective than the other routes. Moreover, there is no guarantee that systemically administrated dexamethasone can go through the blood labyrinth barrier and reach the inner ear effectively. Dexamethasone was not detected in the cochlea until 1 day after surgery in the IP group even though we administrated about 10 times the concentration (10mg/kg) of what is normally used clinically (1mg/kg) for 3 days.

Cochleostomy, in itself, can cause injury or trauma and is known to induce local inflammatory cytokine production which can lead to apoptosis of hair cells through the oxidative stress pathway and trigger immune cell recruitment into the cochlea[41–47]. It is believed that a high concentration of steroid in the cochlea may be feasible in local intracochlear inflammation control. This idea was supported when it was observed that immune response and inflammatory associated genes in the cochlea were down regulated with the use of dexamethasone-eluting electrode and a high intracochlear concentration of dexamethasone was able to reduce fibrosis around the electrode and impedance[38]. However, there was a report showing that despite of the better hearing preservation obtained with local steroid administration, this did not significantly reduce the inflammatory tissue volumes compared to systemic steroid. It was postulated that the steroid induced reduction in intracochlear injury signaling was insufficient to prevent immune cell recruitment into the cochlea[15]. In our study, although we did not test for immune cell recruitment or severity of systemic inflammation, all tested inflammatory cytokines in the cochlea were significantly reduced in the IC and IT groups. With the reduction of TNF-α in the IP group not occurring until 3 days after the surgery, it can be inferred that IP dexamethasone may be less effective compared to the IC and IT routes. This coincided with other reports showing that TNF-α induced hair cell loss[41, 48]. We believe that reducing both intracochlear and systemic inflammation may be important and that IP dexamethasone administration was not effective in reducing intracochlear inflammation.

This study did not investigate and compare the direct effect or injury of an inserted electrode upon the cochlear with the effect of different routes of dexamethasone administration on intracochlear inflammation and residual hearing after cochleosotmy. A higher dexamethasone concentration in the inner ear was observed with the direct intracochlear route than the other routes of administration and the intracochlear inflammation was lesser in the local routes than the systemic route. Residual hearing was better preserved with direct intracochlear dexamethasone administration and histopathologic studies supported this result. Further studies such as combined local and systemic administration and simultaneous evaluation of systemic inflammatory response is needed for a more detailed understanding of the mechanisms involved in controlling intracochlear inflammation.

**Conclusion**

The direct intracochlear delivery route resulted in a higher dexamethasone concentration in the inner ear and lesser intracochlear inflammatory response leading to better hearing preservation than with intratympanic and systemic administration.

**Acknowledgments**

This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) (NRF-2015R1D1A3A01018881 and NRF-2018R1A2B2005022 for Yong-Ho Park)
Author Contributions

Conceptualization: Yong-Ho Park.

Data curation: Ah-Ra Lyu, Dong Hyun Kim, Seung Hun Lee, Dong-Sik Shin, Sun-Ae Shin, Yong-Ho Park.

Formal analysis: Yong-Ho Park.

Funding acquisition: Yong-Ho Park.

Investigation: Ah-Ra Lyu, Dong Hyun Kim, Yong-Ho Park.

Methodology: Ah-Ra Lyu, Dong Hyun Kim, Seung Hun Lee, Dong-Sik Shin, Sun-Ae Shin, Yong-Ho Park.

Project administration: Yong-Ho Park.

Resources: Yong-Ho Park.

Software: Yong-Ho Park.

Supervision: Yong-Ho Park.

Validation: Yong-Ho Park.

Visualization: Yong-Ho Park.

Writing – original draft: Yong-Ho Park.

Writing – review & editing: Yong-Ho Park.

References

1. Maldonado Fernandez M, Kornetsky S, Rubio Rodriguez L. Ethics of Placebo Control in Trials for Idiopathic Sudden Sensorineural Hearing Loss. Otolaryngology—head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2016; 155(1):8–12. Epub 2016/07/03. https://doi.org/10.1177/0194599816644440 PMID: 27371619.

2. Metrailler AM, Babu SC. Management of sudden sensorineural hearing loss. Current opinion in otolaryngology & head and neck surgery. 2016; 24(5):403–6. Epub 2016/07/06. https://doi.org/10.1097/moo.0000000000000287 PMID: 27379548.

3. O’Connell BP, Hunter JB, Haynes DS. Current concepts in the management of idiopathic sudden sensorineural hearing loss. Current opinion in otolaryngology & head and neck surgery. 2016; 24(5):413–9. Epub 2016/06/28. https://doi.org/10.1097/moo.0000000000000289 PMID: 27348351.

4. Rajan GP, Kuthubutheen J, Hedne N, Krishnaswamy J. The role of preoperative, intratympanic glucocorticoids for hearing preservation in cochlear implantation: a prospective clinical study. The Laryngoscope. 2012; 122(1):190–5. Epub 2011/12/21. https://doi.org/10.1002/lary.22142 PMID: 22183635.

5. Cho HS, Lee KY, Choi H, Jang JH, Lee SH. Dexamethasone Is One of the Factors Minimizing the Inner Ear Damage from Electrode Insertion in Cochlear Implantation. Audiology & neuro-otology. 2016; 21(3):178–86. Epub 2016/05/28. https://doi.org/10.1159/000445099 PMID: 27229744.

6. Chang MY, Rah YC, Choi JJ, Woo SW, Hwang YJ, Eastwood H, et al. The Effect of Systemic Steroid on Hearing Preservation After Cochlear Implantation via Round Window Approach: A Guinea Pig Model. Otolaryngology: official publication of the American Otological Society, American Neurotolgy Society [and] European Academy of Otology and Neurotology. 2017; 38(7):962–9. Epub 2017/05/13. https://doi.org/10.1177/0194599817697680 PMID: 28498265.

7. Kil SH, Kalince F. Expression and dexamethasone-induced nuclear translocation of glucocorticoid and mineralocorticoid receptors in guinea pig cochlear cells. Hearing research. 2013; 299:63–78. Epub 2013/02/14. https://doi.org/10.1016/j.heares.2013.01.020 PMID: 23403298; PubMed Central PMCID: PMCPmc3633732.

8. Heinrich UR, Strieth S, Schmidtmann I, Stauber R, Helling K. Dexamethasone prevents hearing loss by restoring glucocorticoid receptor expression in the guinea pig cochlea. The Laryngoscope. 2015. Epub 2015/05/07. https://doi.org/10.1002/lary.25345 PMID: 25946598.
9. Takemura K, Komeda M, Yagi M, Himeno C, Izumikawa M, Doi T, et al. Direct inner ear infusion of dexamethasone attenuates noise-induced trauma in guinea pig. Hearing research. 2004; 196(1–2):58–68. Epub 2004/10/07. https://doi.org/10.1016/j.heares.2004.06.003 PMID: 15464302.

10. Eshraghi AA, Adil E, He J, Graves R, Balkany TJ, Van De Water TR. Local dexamethasone therapy conserves hearing in an animal model of electrode insertion trauma-induced hearing loss. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2007; 28(6):842–8. Epub 2007/05/02. https://doi.org/10.1097/MAO.0b013e31805778fc PMID: 17471110.

11. Morawski K, Telischi FF, Bohorquez J, Niemczyk K. Preventing hearing damage using topical dexamethasone during reversible cochlear ischemia: an animal model. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2009; 30(6):851–7. Epub 2009/07/30. https://doi.org/10.1097/MAO.0b013e3181b12296 PMID: 19638939.

12. Eastwood H, Chang A, Kel G, Sly D, Richardson R, O’Leary SJ. Round window delivery of dexamethasone ameliorates local and remote hearing loss produced by cochlear implantation into the second turn of the guinea pig cochlea. Hearing research. 2010; 265(1–2):25–9. Epub 2010/03/23. https://doi.org/10.1016/j.heares.2010.03.006 PMID: 20303400.

13. Murphy D, Daniel SJ. Intratympanic dexamethasone to prevent cisplatin ototoxicity: a guinea pig model. Otolaryngology—head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2011; 145(3):452–7. Epub 2011/04/28. https://doi.org/10.1177/0022215109342283 PMID: 21521888.

14. Bird PA, Murray DP, Zhang M, Begg EJ. Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2011; 32(6):933–6. Epub 2011/07/05. https://doi.org/10.1097/MAO.0b013e3182255933 PMID: 21725263.

15. Lee J, Ismail H, Lee JH, Kel G, O’Leary J, Hampson A, et al. Effect of both local and systemically administered dexamethasone on long-term hearing and tissue response in a Guinea pig model of cochlear implantation. Audiology & neuro-otology. 2013; 18(6):392–405. Epub 2013/11/07. https://doi.org/10.1159/000353582 PMID: 24192718.

16. Plontke SK, Biegener T, Kammerer B, Delabar U, Salt AN. Dexamethasone concentration gradients along scala tympani after application to the round window membrane. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2008; 29(3):401–6. Epub 2008/02/16. https://doi.org/10.1097/MAO.0b013e318161aaa PMID: 18277312; PubMed Central PMCID: PMCPmc2587453.

17. Balkany TJ, Connell SS, Hodges AV, Payne SL, Telischi FF, Eshraghi AA, et al. Conservation of residual acoustic hearing after cochlear implantation. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2006; 27(8):1083–8. https://doi.org/10.1097/01.mao.0000244355.34577.85 PMID: 17130798.

18. Barbara M, Mattioni A, Monini S, Chiappini I, Ronchetti F, Ballantyne D, et al. Delayed loss of residual hearing in Clarion cochlear implant users. The Journal of laryngology and otology. 2003; 117(11):850–3. Epub 2003/11/07. https://doi.org/10.1258/002221503225242836 PMID: 14670143.

19. Nadol JB Jr, Shiao JY, Burgess BJ, Ketten DR, Eddington DK, Gantz BJ, et al. Histopathology of cochlear implants in humans. The Annals of otology, rhinology, and laryngology. 2001; 110(9):883–91. https://doi.org/10.1258/000348940111000914 PMID: 11558767.

20. Erixon E, Kobler S, Rask-Ander sen H. Cochlear implantation and hearing preservation: Results in 21 consecutively operated patients using the round window approach. Acta oto-laryngologica. 2012; 132(9):923–31. Epub 2012/06/07. https://doi.org/10.3109/000348940111000914 PMID: 11558767.

21. Havenith S, Lammers MJ, Tange RA, Trabalzini F, della Volpe A, van der Heijden GJ, et al. Hearing preservation surgery: cochleostomy or round window approach? A systematic review. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2013; 34(4):667–74. Epub 2013/05/04. https://doi.org/10.1097/MAO.0b013e1318288643e PMID: 23640087.

22. Adunka OF, Dillon MT, Adunka MC, King ER, Pillsbury HC, Buchman CA. Cochleostomy versus round window insertions: influence on functional outcomes in electric-acoustic stimulation of the auditory system. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2014; 35(4):613–8. Epub 2014/02/22. https://doi.org/10.1097/MAO.0b013e318255933 PMID: 24557034.

23. Backous DD. Cochlear implant placement: round window approach. Neurosurgical focus. 2014; 36(1 Suppl):1. Epub 2014/01/02. https://doi.org/10.3171/2013.11.FOCUS13513 PMID: 24380487.
24. Skarzynski H, Podskarbi-Fayette R. A new cochlear implant electrode design for preservation of residual hearing: a temporal bone study. Acta oto-laryngologica. 2010; 130(4):435–42. Epub 2009/11/04. https://doi.org/10.3109/00016480903283733 PMID: 19883172.

25. Woodson EA, Reiss LA, Turner CW, Gfeller K, Gantz BJ. The Hybrid cochlear implant: a review. Advances in oto-rhinology. 2010; 67:125–34. https://doi.org/10.1159/000262604 PMID: 19955729.

26. Stathopoulos D, Chambers S, Enke YL, Timbol G, Risi F, Miller C, et al. Development of a safe dexamethasone-eluting electrode array for cochlear implantation. Cochlear implants international. 2014; 15(5):254–63. Epub 2014/03/14. https://doi.org/10.1179/1754762813Y.0000000054 PMID: 24621150.

27. Bohl A, Rohm HW, Cesphi P, Paasche G, Hahn A, Barickowski S, et al. Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear. Journal of materials science Materials in medicine. 2012; 23(9):2151–62. Epub 2012/06/19. https://doi.org/10.1007/s10856-012-4698-z PMID: 22706626.

28. Liu Y, Jolly C, Braun S, Janssen T, Scherer E, Steinhoff J, et al. Effects of a dexamethasone-releasing implant on cochlea: A functional, morphological and pharmakinetik study. Hearing research. 2015; 327:89–101. Epub 2015/05/20. https://doi.org/10.1016/j.heares.2015.04.019 PMID: 25987502.

29. Takumi Y, Nishio SY, Mugridge K, Oguchi T, Hashimoto S, Suzuki N, et al. Gene expression pattern after insertion of dexamethasone-eluting electrode into the guinea pig cochlea. PloS one. 2014; 9(10):e110238. Epub 2014/10/21. https://doi.org/10.1371/journal.pone.0110238 PMID: 25329543; PubMed Central PMCID: PMC4203000.

30. Douchement D, Terranti A, Lamblin J, Salleron J, Siepmann F, Siepmann J, et al. Dexamethasone eluting electrodes for cochlear implantation: Effect on residual hearing. Cochlear implants international. 2015; 16(4):195–200. Epub 2014/03/07. https://doi.org/10.1179/1754762813Y.0000000053 PMID: 24939762.

31. Salt AN, Hartsock J, Plontke S, LeBel C, Piu F. Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation. Audiology & neuro-otology. 2011; 16(5):323–35. Epub 2010/12/24. https://doi.org/10.1097/MAO.0b013e31819173ec PMID: 21178339; PubMed Central PMCID: Pmc4203767.

32. Sun C, Wang X, Chen D, Lin X, Yu D, Wu H. Dexamethasone loaded nanoparticles exert protective effects against Cisplatin-induced hearing loss by systemic administration. Neuroscience letters. 2016; 619:142–8. Epub 2016/03/15. https://doi.org/10.1016/j.neulet.2016.03.012 PMID: 26971791.

33. Salehi P, Akinpelu OV, Waissbluth S, Peleva E, Meehan B, Rak J, et al. Attenuation of cisplatin ototoxicity by otoprotective effects of nanoencapsulated curcumin and dexamethasone in a guinea pig model. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2014; 35(7):1131–9. Epub 2014/05/21. https://doi.org/10.1097/MAO.0000000000000403 PMID: 24841915.

34. El Kechai N, Mamelle E, Nguyen Y, Huang N, Nicolas V, Chaminade P, et al. Hyaluronic acid liposomal gel sustains delivery of a corticoid to the inner ear. Journal of controlled release: official journal of the Controlled Release Society. 2016; 226:248–57. Epub 2016/02/11. https://doi.org/10.1016/j.jconrel.2016.02.013 PMID: 26860286.

35. James DP, Eastwood H, Richardson RT, O’Leary SJ. Effects of round window dexamethasone on residual hearing in a Guinea pig model of cochlear implantation. Audiology & neuro-otology. 2008; 13(2):86–96. Epub 2007/12/07. https://doi.org/10.1159/000117780 PMID: 18057872.

36. Vivero RJ, Joseph DE, Angeli S, He J, Chen S, Eshraghi AA, et al. Dexamethasone base conserves hearing from electrode trauma-induced hearing loss. The Laryngoscope. 2008; 118(11):2028–35. Epub 2008/09/27. https://doi.org/10.1007/MLG.0b013e31818173ec PMID: 18818553.

37. Kuthubutheen J, Coates H, Rowell C, Nedzelski J, Chen JM, Lin V. The role of extended preoperative steroids in hearing preservation cochlear implantation. Hearing research. 2015; 327:257–64. Epub 2015/06/29. https://doi.org/10.1016/j.heares.2015.06.010 PMID: 26117408.

38. Wilk M, Hessler R, Mugridge K, Jolly C, Fehr M, Lenarz T, et al. Impedance Changes and Fibrous Tissue Growth after Cochlear Implantation Are Correlated and Can Be Reduced Using a Dexamethasone Eluting Electrode. PloS one. 2016; 11(2):e0147552. Epub 2016/02/04. https://doi.org/10.1371/journal.pone.0147552 PMID: 26840740; PubMed Central PMCID: PMC4739581.

39. John SK, Hamaguchi Y, Goycoolea M. Review of round window membrane permeability. Acta oto-laryngologica Suplementum. 1989; 459:43–8. Epub 1989/01/01. PMID: 2648755.

40. John SK, Hunter BA, Odland RM. Blood-labyrinth barrier and fluid dynamics of the inner ear. The international tinnitus journal. 2001; 7(2):72–83. Epub 2003/12/24. PMID: 14689642.

41. Keithley EM, Wang X, Barkdull GC. Tumor necrosis factor alpha can induce recruitment of inflammatory cells to the cochlea. Otology & neurotology: official publication of the American Otological Society,
American Neurotology Society [and] European Academy of Otology and Neurotology. 2008; 29(6):854–9. Epub 2008/07/19. https://doi.org/10.1097/MAO.0b013e31818256a9 PMID: 18636025.

42. van de Water TR, Dinh CT, Vivero R, Hoosien G, Eshraghi AA, Balkany TJ. Mechanisms of hearing loss from trauma and inflammation: otoprotective therapies from the laboratory to the clinic. Acta oto-laryngologica. 2010; 130(3):308–11. Epub 2009/07/07. https://doi.org/10.1080/00016480903124655 PMID: 19579145.

43. Jia H, Wang J, Francois F, Uziel A, Puel JL, Venail F. Molecular and cellular mechanisms of loss of residual hearing after cochlear implantation. The Annals of otology, rhinology, and laryngology. 2013; 122(1):33–9. Epub 2013/03/12. https://doi.org/10.1177/00034894122200107 PMID: 23472314.

44. Seyyedi M, Nadol JB Jr. Intracochlear inflammatory response to cochlear implant electrodes in humans. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2014; 35(9):1545–51. Epub 2014/08/15. https://doi.org/10.1097/mao.0000000000000540 PMID: 25122600; PubMed Central PMCID: PMCPmc4165780.

45. Ryu KA, Lyu AR, Park H, Choi JW, Hur GM, Park YH. Intracochlear Bleeding Enhances Cochlear Fibrosis and Ossification: An Animal Study. PloS one. 2015; 10(8):e0136617. Epub 2015/08/27. https://doi.org/10.1371/journal.pone.0136617 PMID: 26308864; PubMed Central PMCID: PMCPmc4550248.

46. Zhang H, Stark G, Reiss L. Changes in Gene Expression and Hearing Thresholds After Cochlear Implantation. Otology & neurotology: official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology. 2015; 36(7):1157–65. Epub 2015/05/15. https://doi.org/10.1097/mao.0000000000000787 PMID: 25970030; PubMed Central PMCID: PMCPmc4884452.

47. Kaur T, Zamani D, Tong L, Rubel EW, Ohlemiller KK, Hirose K, et al. Fractalkine Signaling Regulates Macrophage Recruitment into the Cochlea and Promotes the Survival of Spiral Ganglion Neurons after Selective Hair Cell Lesion. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2015; 35(45):15050–61. Epub 2015/11/13. https://doi.org/10.1523/jneurosci.2325-15.2015 PMID: 26588776; PubMed Central PMCID: PMCPmc4642237.

48. Haake SM, Dinh CT, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone protects auditory hair cells against TNFalpha-initiated apoptosis via activation of PI3K/Akt and NFkappaB signaling. Hearing research. 2009; 255(1–2):22–32. Epub 2009/05/16. https://doi.org/10.1016/j.heares.2009.05.003 PMID: 19442713.